AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22449658
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (n=74, 3 g intravenous injection before the procedure and oral 1 g per day for 2 days after the procedure)
Trial: 15667874
Drug: 2% rectal
RxNorm normalized name: Ana-Lex, 2%-2% rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% rectal lidocaine gel
Trial: 15667874
Drug: Perianal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perianal injection of 1% lidocaine
Trial: 15667874
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (lidocaine gel)
Trial: 11336160
Drug: Normal fructose
RxNorm normalized name: Fructose
DrugBank: Fructose (DB04173)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Normal fructose absorption
Trial: 31077858
Drug: Antibacterials in
RxNorm normalized name: OTHER ANTIBACTERIALS in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterials in outpatient prescriptions at township health centers
Trial: 31077858
Drug: Antibacterials in
RxNorm normalized name: OTHER ANTIBACTERIALS in ATC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibacterials in outpatient prescriptions at community health service centers
Trial: 23609776
Drug: Insoluble wheat
RxNorm normalized name: WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insoluble wheat bran fibre-containing breakfast cereal (5.4 g fibre, 3.5 g from wheat bran)
Trial: 21606430
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus DTIC (10 mg/m2/min at 1800 mg/m2 followed by DTIC at 500 mg/m2 every 2 weeks)
Trial: 21606430
Drug: DTIC alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC alone (1200 mg/m2 every 3 weeks)
Trial: 19194189
Drug: Low Hb
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Hb level (<12 g/dL)
Trial: 16126256
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment with rtPA
Trial: 16126256
Drug: No thrombolytic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No thrombolytic treatment (Control)
Trial: 15330958
Drug: 22‐G hollow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22‐G hollow needle (group I)
Trial: 15330958
Drug: 22‐G caudal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 22‐G caudal block needle (group II)
Trial: 11233236
Drug: Neoadjuvant radiochemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radiochemotherapy (40 Gy radiation, low-dose fraction cisplatin 7 mg/body/day for 5 days a week for 4 weeks, and 5-fluorouracil 350 mg/body/day for 28 days)
Trial: 11233236
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (high-dose fraction cisplatin 70 mg/m2/day on day 1 and 5-fluorouracil 700 mg/m2/day on days 1-5)
Trial: 9253574
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PGE1-induced hypotension and haemodilution (Group D)
Trial: 8494421
Drug: St. Thomas'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. Thomas' Hospital solution (STS)
Trial: 29522355
Drug: NaNO3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaNO3 supplementation (1 g/day, n = 13)
Trial: 27980499
Drug: Caffeine supplementation
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine supplementation (6 mg∙kg‐1 body mass anhydrous caffeine)
Trial: 25319951
Drug: Rosuvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (20 mg 12 h before PCI, and a further 20 mg 2 h preprocedure)
Trial: 22678167
Drug: Trimethoprim-sulfamethoxazole (DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (DS twice daily)
Trial: 12602406
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of metformin and glucose-lowering sulphonylurea
Trial: 30052328
Drug: Alicapistat 400-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alicapistat 400- or 800-mg twice-daily doses
Trial: 30052328
Drug: Donepezil 10
RxNorm normalized name: donepezil 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 10 mg twice daily (active control)
Trial: 30052328
Drug: Alicapistat (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alicapistat (various doses)
Trial: 19460767
Drug: ADX10059 250
RxNorm normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX10059 250 mg tds
Trial: 19460767
Drug: ADX10059 50
RxNorm normalized name: ADX10059
DrugBank: ADX10059 (DB05070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADX10059 50 mg tds
Trial: 17172351
Drug: docetaxel 60
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 60 mg/m2 and cisplatin 50 mg/m2
Trial: 17172351
Drug: paclitaxel 175
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175 mg/m2 and cisplatin 50 mg/m2
Trial: 7672876
Drug: Contractubex gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contractubex gel (10% onion extract, 50/U of sodium heparin per 1g of gel, 1% allantoin), applied topically for one year starting 26 days post-operation.
Trial: 2919059
Drug: Chlorhexidine 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.1% mouthrinses (rinsed four times daily)
Trial: 22849770
Drug: ACT‐178882 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT‐178882 (single dose 30 mg in fed state)
Trial: 22849770
Drug: ACT‐178882 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT‐178882 (multiple doses 30‐600 mg once daily for 14 days)
Trial: 22849770
Drug: ACT‐178882 (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT‐178882 (single doses 10‐1000 mg)
Trial: 22849770
Drug: ACT‐178882 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT‐178882 (multiple doses)
Trial: 21742303
Drug: Low-fluence photodynamic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fluence photodynamic therapy (PDT)
Trial: 24729079
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of ranibizumab
Trial: 14695940
Drug: Short term
RxNorm normalized name: Short Term Oral Swab System KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short term administration of a nutraceutical formulation based on coenzyme Q10, vitamin E, selenium, methionine, and phospholipids
Trial: 10649623
Drug: Pnc conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pnc conjugate vaccine (1, 3, or 10 micrograms of PSs conjugated to diphtheria or tetanus toxoid)
Trial: 10649623
Drug: Pnc conjugate
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pnc conjugate vaccine
Trial: 8783392
Drug: Regular nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Regular nicotine cigarette (0.7 mg)
Trial: 8783392
Drug: Denicotinised cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denicotinised cigarette (0.1 mg)
Trial: 2937411
Drug: celiprolol hydrochloride
RxNorm normalized name: Celiprolol hydrochloride
DrugBank: Celiprolol (DB04846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol hydrochloride (300 mg once daily for 4 weeks)
Trial: 26232049
Drug: Intravenous IgG
RxNorm normalized name: Human IGG
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous IgG administered at replacement dosages
Trial: 20556613
Drug: Regimen B
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B (docetaxel with 150 mg single-dose oral casopitant)
Trial: 18940393
Drug: Sibutramine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (10 mg/d) with pioglitazone (30 mg/d)
Trial: 18940393
Drug: Pioglitazone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (30 mg/d) + Placebo
Trial: 16801406
Drug: Telbivudine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 200 mg/day
Trial: 16801406
Drug: Telbivudine 600
RxNorm normalized name: telbivudine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 600 mg/day
Trial: 16801406
Drug: Telbivudine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine with lamivudine (100 mg/day)
Trial: 16801406
Drug: Telbivudine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine with adefovir dipivoxil (10 mg/day)
Trial: 12974995
Drug: Paroxetine augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine augmentation
Trial: 12974995
Drug: Paroxetine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (in patients with lithium levels <=0.8 mequiv./l)
Trial: 12974995
Drug: Moclobemide monotherapy
RxNorm normalized name: moclobemide
DrugBank: Moclobemide (DB01171)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide monotherapy
Trial: 10831173
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) infusion of 3.3 mmol/kg lysine hydrochloride over 90 minutes
Trial: 23174399
Drug: Ranibizumab monotherapy
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ranibizumab monotherapy (control)
Trial: 16575739
Drug: Posaconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole (200 mg on day 1, followed by 100 mg/day for 13 days)
Trial: 16575739
Drug: Fluconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluconazole (200 mg on day 1, followed by 100 mg/day for 13 days)
Trial: 12676389
Drug: Prostaglandin E(2)
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E(2) tablets
Trial: 9163863
Drug: CyA-ME (microemulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA-ME (microemulsion formulation)
Trial: 9163863
Drug: CyA-GC (corn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA-GC (corn oil-based gel capsule)
Trial: 1546124
Drug: Toloxatone 1000
RxNorm normalized name: toloxatone
DrugBank: Toloxatone (DB09245)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toloxatone 1000 mg/day
Trial: 3096181
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate therapy (variable doses based on initial arterial pH)
Trial: 29109363
Drug: 0.033 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.033 mg/kg/day Norditropin® (somatropin)
Trial: 29109363
Drug: 0.066 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.066 mg/kg/day Norditropin® (somatropin)
Trial: 29109363
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between 0.033 mg/kg/day and 0.066 mg/kg/day
Trial: 27298411
Drug: Chemotherapy (epirubicin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (epirubicin, cisplatin, and fluorouracil)
Trial: 19242554
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (20 g/day loading dose for 5 days, followed by 4.8 g/day maintenance)
Trial: 19242554
Drug: Placebo (equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (equivalent number of placebo capsules)
Trial: 9931883
Drug: Intraperitoneal active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal active charcoal-mitomycin C therapy (MMC‐CH)
Trial: 9931883
Drug: R0 resection
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R0 resection with MMC‐CH therapy
Trial: 22123270
Drug: Nefopam 30
RxNorm normalized name: nefopam 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 30 mg tablet (Acupan®)
Trial: 18485252
Drug: Topical application
RxNorm normalized name: Talc Topical application Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of pure natural honey during concomitant chemotherapy and radiotherapy
Trial: 18485252
Drug: Concomitant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant chemotherapy and radiotherapy without honey (Control)
Trial: 11721378
Drug: Leunase 6,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leunase 6,000 KU/m2, continuous intravenous injection every day for 8 times
Trial: 11721378
Drug: Leunase 6,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leunase 6,000 KU/m2, continuous intravenous injection every other day for 8 times
Trial: 7585846
Drug: Intravenous ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ganciclovir (5 mg/kg as a 1-hour i.v. infusion every 24 hours)
Trial: 7585846
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 500 mg every 3 hours (six times daily) for 3 days
Trial: 7585846
Drug: Oral ganciclovir
RxNorm normalized name: Ganciclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ganciclovir 1,000 mg TID for 3 days
Trial: 28750935
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir 400 mg plus rilpivirine 600 mg (4-week group)
Trial: 28750935
Drug: Long-acting cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting cabotegravir 600 mg plus rilpivirine 900 mg (8-week group)
Trial: 28750935
Drug: Oral cabotegravir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cabotegravir plus abacavir-lamivudine (oral treatment group)
Trial: 28750935
Drug: Injection-site reactions
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection-site reactions (all groups)
Trial: 28750935
Drug: Serious adverse
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serious adverse events (intramuscular groups)
Trial: 28750935
Drug: Serious adverse
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Serious adverse events (oral treatment group)
Trial: 25700386
Drug: Iron and
RxNorm normalized name: beef,iron and wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron and folic acid supplements (Control)
Trial: 19184686
Drug: Mock prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mock prescriptions
Trial: 11956353
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion at 3 kcal min(‐1)
Trial: 11956353
Drug: Intraduodenal glucose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraduodenal glucose infusion at 1 kcal min(‐1)
Trial: 9589821
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 0.1% cream pretreatment
Trial: 9589821
Drug: Testosterone transdermal
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone transdermal delivery (TTD) without pretreatment
Trial: 8028511
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (0.03 mg.kg ideal body weight‐1.d‐1)
Trial: 241366
Drug: i.v. diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. diazepam (0.3 mg/kg)
Trial: 241366
Drug: i.v. flunitrazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. flunitrazepam (0.03 mg/kg) combined with pethidine (1 mg/kg)
Trial: 241366
Drug: i.v. droperidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. droperidol (5 mg) combined with fentanyl (0.2 mg)
Trial: 241366
Drug: i.v. diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. diazepam (0.3 mg/kg) combined with pethidine (1 mg/kg)
Trial: 20947493
Drug: distributed constraint‐induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: distributed constraint‐induced therapy (dCIT)
Trial: 20947493
Drug: control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control treatment (CT)
Trial: 17309447
Drug: Intralipid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid infusion for 2 hours
Trial: 17309447
Drug: Control infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control infusion (Glycerol)
Trial: 2569194
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg dextropropoxyphene napsylat (DP) daily for 16 days
Trial: 64951
Drug: Bleomycin (intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin (intramuscular injection)
Trial: 64951
Drug: Bleomycin (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bleomycin (intravenous injection)
Trial: 28353144
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg daily for 2 months)
Trial: 28353144
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (40 mg for 2 weeks per month for 2 months)
Trial: 23738545
Drug: Cognitive processing
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive processing therapy (1 individual session and 11 group sessions)
Trial: 15292036
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding (control group)
Trial: 12837670
Drug: Risperidone 2
RxNorm normalized name: risperidone 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 2 mg/day
Trial: 15353388
Drug: Risperidone 0.5
RxNorm normalized name: risperidone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone 0.5 mg/day
Trial: 8261811
Drug: Topical glycolic
RxNorm normalized name: glycolate Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glycolic acid lotion
Trial: 3949246
Drug: Intra-abdominal instillation
RxNorm normalized name: ALCOHOL 80 mL in 100 mL INTRA-ABDOMINAL LIQUID [80% Alcohol Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-abdominal instillation of bupivacaine 2 mg/kg bw
Trial: 3052266
Drug: Bromocriptine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (up to 30 mg per day)
Trial: 31154887
Drug: Cognitive behaviour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behaviour language therapy (CBLT) programme delivered in 24 group sessions over 12 weeks
Trial: 23433852
Drug: Once-daily DRV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily DRV/r
Trial: 23433852
Drug: Twice-daily DRV/r
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily DRV/r
Trial: 20840345
Drug: Licochalcone A
RxNorm normalized name: Licochalcone A
DrugBank: Licochalcone A (DB19281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Licochalcone A (LA) lotion, applied twice daily for 6 weeks
Trial: 20840345
Drug: Hydrocortisone (HC)
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone (HC) lotion, applied twice daily for 6 weeks
Trial: 17301824
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg/daily)
Trial: 17301824
Drug: Combined (losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined (losartan 50 mg/daily + ramipril 5 mg/daily)
Trial: 9932142
Drug: GLA +
RxNorm normalized name: GLA
DrugBank: Gamolenic acid (DB13854)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLA + EPA (continued treatment)
Trial: 3056506
Drug: Metronidazole treatment
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole treatment (2 g single doses on days 1 and 3) for male partners
Trial: 3056506
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for male partners
Trial: 28669288
Drug: MOMCare collaborative
RxNorm normalized name: ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MOMCare collaborative care depression intervention (choice of brief interpersonal psychotherapy or pharmacotherapy or both)
Trial: 22878873
Drug: Sequential HRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential HRP scoring protocol (automatic and then manual for residual cases)
Trial: 19338158
Drug: Salvia injection
RxNorm normalized name: SALVIA OFFICINALIS
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salvia injection (SI) plus composite amino acid (CAA) for 7 days
Trial: 15255164
Drug: irinotecan in
RxNorm normalized name: irinotecan Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan in combination with gemcitabine, taxanes, and other new agents